Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

• Published in: JHEP reports 2023-10, Vol.5 (10), p.100847-100847, Article 100847
• Main Authors: Lim, Young-Suk, Chan, Henry L.Y., Ahn, Sang Hoon, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry L.A., Pan, Calvin Q., Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Shalimar, Brunetto, Maurizia, Hui, Aric Josun, Chang, Ting-Tsung, Lim, Seng Gee, Abramov, Frida, Flaherty, John F., Wang, Hongyuan, Yee, Leland J., Kao, Jia-Horng, Gane, Edward, Hou, Jinlin, Buti, Maria
• Format: Article
• Language: English
• Subjects: aMAP; antiviral therapy; incidence; mPAGE-B; REACH-B
• ISSN: 2589-5559; 2589-5559
• DOI: 10.1016/j.jhepr.2023.100847

Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated. Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p